Enara Bio Ltd. is staking a claim to having validated the first in a new class of tumor antigens derived from unannotated ...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial ...
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data ...
ME Therapeutics Holdings Inc., a publicly listed biotechnology company working on novel cancer-fighting drugs in the field of ...
Conclusion Fully human anti-GPRC5D CAR-T therapy RD118 demonstrated a 94.4% ORR and a median PFS of 18.2 months with a manageable safety profile in heavily over pretreated R/R MM, including patients ...
T-cell engagers, especially BiTEs, show promise in treating solid tumors by targeting tumor-associated antigens and redirecting T-cell activity. Tarlatamab, targeting DLL3 in SCLC, demonstrated ...
DuoCAR20.19.22-D95 targets CD19, CD20, and CD22, addressing antigen escape in B-cell malignancies like B-ALL and B-NHL. Early-stage trials show no safety concerns for DuoCAR20.19.22-D95, with ongoing ...
Genentech is continuing its summer of downsizing and cost-cutting, this time with plans to terminate a cell therapy deal worth as much as $2 billion. The pact is with Adaptive Biotechnologies and ...
Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback